Register for our free email digests:
University of Manchester
Latest From Amplimmune Inc.
This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.
Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.
GenVec, a clinical-stage biopharmaceutical company focused on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines, has named Michael Richman to its board of directors. Mr Richman has been president and CEO of Amplimmune, a member of the AstraZeneca group since 2013.
The profound achievements of the pharma, biotech and allied industries were celebrated last night at the annual Scrip Awards in London.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.